OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube

      Site: OncologyTube

    • Products & Pricing
      • Banner Advertising Plans
      • Pre-Roll Advertising
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
      • Create A Deep Dive Conversation
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5574
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia 5574
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9
Menin MLL Inhibitor for NPM1 AML: The next steps in treatment
0:01:15

Menin MLL Inhibitor for NPM1 AML: The next steps in treat...

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study.

___________

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, "Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia," will be published in the journal's January 31, 2020 issue and is currently available online.

This study examined the activity of VTP-50469, an orally-available inhibitor of MLL1-Menin interaction and close analog of the Company's lead Menin inhibitor, SNDX-5613, for the treatment of established NPM1 AML and the possible prevention of the disease in high-risk populations. Using preclinical models of NPM1 AML, the authors established that the presence of an NPM1 mutation is a clear indicator of pre-leukemic activity and represents a critical step in the development of AML. VTP-50469 was shown to eradicate NPM1 mutant cells at various stages of disease development, suggesting that Menin-MLL inhibition could potentially serve either as a targeted preventive therapy or as a treatment of established disease.

"These unprecedented findings highlight the potential for single agent Menin-MLL inhibition to rapidly eradicate fully developed NPM1 mutant leukemia, even in the case of aggressive relapsed AML," said Scott A. Armstrong, M.D., Ph.D., President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and Chairman, Department of Pediatric Oncology, Dana-Farber Cancer Institute, and senior author of the study. "In addition, these results provide support for a Menin-MLL inhibitor to serve as a novel strategy to prevent AML development in high-risk patient populations, as NPM1 mutations are acquired in pre-leukemic clones."

"NPM1 mutant AML represents the most common type of cytogenetically normal AML," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "On the heels of our recent Cancer Cell publication, these findings add to the growing body of compelling preclinical data supporting the potential for SNDX-5613 to serve as an effective intervention for both NPM1 mutant AML and MLL-r acute leukemias. We are committed to providing patients with more targeted therapeutic options and are hopeful that these findings will translate into the clinic in our ongoing Phase 1/2 AUGMENT-101 trial."

Read here: https://www.oncologytube.com/video/science-magazine-publishes-results-from-preclinical-study-on-the-activity-of-menin-mll-inhibition-for-the-treatment-of-npm1-acute-myeloid-leukemia

21 Views
2 years ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Acute Myelogenous Leukemia

Case #1: New Possibilities for Maintenance Therapy in AML
0:01:20
Case #1: New Possibilities for Maintenance Therapy in AML
4 Views
3 weeks ago
ACHL
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast-Yishai Ofran, MD @ShaareZedekMed #ASH21 #E2906 #AML #Cancer #Research Phase III Prospective E2906 Trial
0:07:16
Podcast-Yishai Ofran, MD @ShaareZedekMed #ASH21 #E2906 #A...
7 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Yishai Ofran, MD @ShaareZedekMed #ASH21 #E2906 #AML #Cancer #Research Phase III Prospective E2906 Trial
0:07:16
Yishai Ofran, MD @ShaareZedekMed #ASH21 #E2906 #AML #Canc...
15 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast-Courtney D. DiNardo, MD @MDAndersonNews @UTAustin #ASH21 #AML #Leukemia #Cancer #Research Phase III IDHentify Trial
0:07:57
Podcast-Courtney D. DiNardo, MD @MDAndersonNews @UTAustin...
26 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Courtney D. DiNardo, MD @MDAndersonNews @UTAustin #ASH21 #AML #Leukemia #Cancer #Research Phase III IDHentify Trial
0:07:57
Courtney D. DiNardo, MD @MDAndersonNews @UTAustin #ASH21 ...
50 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast-Karuppiah Kannan, PhD @TakedaPharma #ASH21 #NonHodgkinsLymphoma #MultipleMyeloma #Cancer #Research ASH 2021 Abstracts 2488 And 2742 SUMO-Activating Enzyme Inhibitor
0:15:56
Podcast-Karuppiah Kannan, PhD @TakedaPharma #ASH21 #NonHo...
18 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Karuppiah Kannan, PhD @TakedaPharma #ASH21 #NonHodgkinsLymphoma #MultipleMyeloma #Cancer #Research ASH 2021 Abstracts 2488 And 2742 SUMO-Activating Enzyme Inhibitor
0:15:56
Karuppiah Kannan, PhD @TakedaPharma #ASH21 #NonHodgkinsLy...
66 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast-Naval Daver, MD @Daver_Leukemia @MDAndersonNews #ASH21 #AML #Cancer #Research Phase III ENHANCE-2 Trial
0:09:39
Podcast-Naval Daver, MD @Daver_Leukemia @MDAndersonNews #...
20 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Magrolimab + Azacitidine vs Venetoclax Acute Myeloid Leukemia
0:09:39
Magrolimab + Azacitidine vs Venetoclax Acute Myeloid Leuk...
112 Views
7 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast- Professor Andrew Wei- Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemothera...
0:13:27
Podcast- Professor Andrew Wei- Long-Term Overall Survival...
5 Views
8 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Professor Andrew Wei- Professor Andrew Wei- Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensi...
0:13:27
Professor Andrew Wei- Professor Andrew Wei- Long-Term Ove...
18 Views
8 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast- Eunice S. Wang, MD- 700 Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients I...
0:07:44
Podcast- Eunice S. Wang, MD- 700 Phase 3, Open-Label, Ran...
9 Views
8 months ago
ASH
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Copyright 2022 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592